Medicare Oncology Payment Program Could Pressure Part D Prices, Industry Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A new Oncology Payment Model for Medicare will test episode-of-care payment for chemotherapy and offer incentives for keeping costs low, but biopharma firms are concerned that inclusion of Part D-covered cancer drugs in the cost measurement will intensify pressure on prices.